Oxbryta came to market in 2019, a few days after Novartis' injectable anti-P-selectin antibody Adakveo (crizanlizumab), which is also tipped for blockbuster sales but like Oxbryta has suffered ...

The interplay between hypoxic and acidic conditions in the tumor microenvironment is unclear. Here, the authors show that hypoxic and acidic tumor cells do not fully overlap and display a ...

After hours: November 22 at 7:52 p.m. EST ...